Xencor (XNCR) Free Cash Flow (2013 - 2026)
Xencor (XNCR) posted quarterly Free Cash Flow of -$68.2 million for Q1 2026, down 286.31% year-over-year from $36.6 million in Q1 2025, and down 29.11% quarter-over-quarter from -$52.9 million in Q4 2025.
Powered by 
Analysis
Xencor (XNCR) Free Cash Flow (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Free Cash Flow for 14 consecutive years, with -$68.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 286.31% year-over-year to -$68.2 million; the TTM figure through Mar 2026 stood at -$188.8 million (down 11.77% YoY), while the FY2025 annual figure was -$138.3 million, up 33.62% from the prior year.
- Free Cash Flow fell to -$68.2 million in Q1 2026 per XNCR's latest filing, from -$52.9 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $31.9 million in Q2 2022 and bottomed at -$70.4 million in Q2 2024.
- Historically, Free Cash Flow has averaged -$30.9 million across 5 years, with a median of -$34.4 million in 2022.
- Annual changes were most pronounced in 2022 — Free Cash Flow jumped 367.36% — and 2023, when it tumbled 1211.03%.
- Xencor's Free Cash Flow stood at -$34.4 million in 2022, then jumped by 149.97% to $17.2 million in 2023, then sank by 399.62% to -$51.5 million in 2024, then fell by 2.62% to -$52.9 million in 2025, then decreased by 29.11% to -$68.2 million in 2026.
- Business Quant data shows XNCR's Free Cash Flow at -$68.2 million in Q1 2026, -$52.9 million in Q4 2025, and -$31.0 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Xencor | 2.02 Bn | 1.65 Bn | - | -56.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -56.20 Mn |
| Mar 31, 2026 | -68.24 Mn |
| Dec 31, 2025 | -52.85 Mn |
| Sep 30, 2025 | -31.00 Mn |
| Jun 30, 2025 | -36.75 Mn |
| Mar 31, 2025 | -17.66 Mn |
| Dec 31, 2024 | -51.50 Mn |
| Sep 30, 2024 | -29.42 Mn |
| Jun 30, 2024 | -70.38 Mn |
| Mar 31, 2024 | -56.99 Mn |
| Dec 31, 2023 | 17.19 Mn |
| Sep 30, 2023 | -30.11 Mn |
| Jun 30, 2023 | -42.05 Mn |
| Mar 31, 2023 | -41.40 Mn |
| Dec 31, 2022 | -34.40 Mn |
| Sep 30, 2022 | -15.25 Mn |
| Jun 30, 2022 | 31.92 Mn |
| Mar 31, 2022 | 3.73 Mn |
| Dec 31, 2021 | 55.47 Mn |
| Sep 30, 2021 | -41.77 Mn |